Table 2.
Treatment of Austrian patients with stable CAD and Austrian patients with stable CAD and angina during observation (N [%])a
| Parameter | Baseline | 1st year | 2nd year | 3rd year | 4th year | 5th year |
|---|---|---|---|---|---|---|
| Patients with stable CAD (N [%]) | ||||||
| N | 424 | 411 | 351 | 337 | 323 | 305 |
| Aspirin | 367 (86.6) | 333 (82.2) | 268 (79.1) | 248 (75.8) | 231 (74.5) | 213 (73.2) |
| Thienopyridines | 38 (9.0) | 42 (10.4) | 35 (10.3) | 34 (10.4) | 34 (11.0) | 30 (10.3) |
| Other antiplatelet agent | 44 (10.4) | 39 (9.6) | 31 (9.1) | 34 (10.4) | 32 (10.3) | 33 (11.3) |
| Oral anticoagulant | 46 (10.8) | 44 (10.9) | 45 (13.3) | 45 (13.8) | 48 (15.5) | 46 (15.8) |
| Beta-blocker | 334 (78.8) | 304 (75.1) | 249 (73.5) | 235 (71.9) | 223 (71.9) | 202 (69.4) |
| Ivabradine | 25 (5.9) | 26 (6.4) | 18 (5.3) | 17 (5.2) | 15 (4.8) | 16 (5.5) |
| Calcium antagonists | 76 (17.9) | 74 (18.3) | 60 (17.7) | 63 (19.3) | 55 (17.7) | 52 (17.9) |
| Verapamil or dilitiazem | 15 (3.5) | 15 (3.7) | 11 (3.2) | 10 (3.1) | 8 (2.6) | 6 (2.1) |
| ACE inhibitors | 191 (45.0) | 175 (43.2) | 145 (42.8) | 134 (41.0) | 122 (39.4) | 117 (40.2) |
| AT II receptor-blocker | 120 (28.4) | 120 (29.6) | 105 (31.0) | 100 (30.6) | 97 (31.3) | 89 (30.6) |
| LLD | 401 (94.6) | 378 (93.3) | 316 (93.2) | 300 (91.7) | 284 (91.6) | 267 (91.8) |
| Statins (if LLD) | 358 (89.3) | 321 (84.9) | 261 (82.6) | 246 (82.0) | 230 (81.0) | 213 (79.8) |
| Other antianginal agent | 50 (11.8) | 50 (12.3) | 38 (11.2) | 40 (12.2) | 37 (11.9) | 32 (11.0) |
| Trimetazine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Ranolazine | 0 (0.0) | 1 (0.2) | 2 (0.6) | 4 (1.2) | 4 (1.3) | 3 (1.0) |
| Diuretics | 140 (33.0) | 135 (33.3) | 119 (35.1) | 111 (33.9) | 111 (35.8) | 105 (36.1) |
| Other hypertensive agent | 47 (11.1) | 50 (12.3) | 39 (11.5) | 36 (11.0) | 34 (11.0) | 29 (10.0) |
| Digoxin and derivates | 10 (2.4) | 9 (2.2) | 8 (2.4) | 7 (2.1) | 7 (2.3) | 9 (3.1) |
| Amiodarone/dronedarone | 17 (4.0) | 16 (4.0) | 13 (3.8) | 13 (4.0) | 12 (3.9) | 11 (3.8) |
| Other antiarrhythmics | 8 (1.9) | 8 (2.0) | 10 (2.9) | 8 (2.4) | 8 (2.6) | 7 (2.4) |
| Other medication | ||||||
| NSAIDs | 44 (10.4) | 44 (10.9) | 35 (10.3) | 28 (8.6) | 27 (8.7) | 22 (7.6) |
| Antidiabetic agents | 82 (19.3) | 76 (18.8) | 56 (16.5) | 56 (17.2) | 54 (17.4) | 53 (18.4) |
| PPI | 151 (35.6) | 144 (35.6) | 114 (33.5) | 106 (32.6) | 109 (35.2) | 99 (34.4) |
| THoR | 48 (11.3) | 47 (11.6) | 40 (11.8) | 39 (12.0) | 36 (11.6) | 31 (10.8) |
| HoR | 1 (0.2) | 1 (0.2) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 1 (0.3) |
| Drug for ED | 8 (1.9) | 8 (2.0) | 5 (1.5) | 5 (1.5) | 4 (1.3) | 3 (1.0) |
| Patients with stable CAD and angina | ||||||
| N | 46 | 35 | 25 | 14 | 16 | 7 |
| Aspirin | 43 (93.5) | 28 (80.0) | 20 (80.0) | 13 (92.9) | 13 (81.2) | 5 (71.4) |
| Thienopyridines | 4 (8.7) | 6 (17.1) | 7 (28.0) | 1 (7.1) | 2 (12.5) | 0 (0.0) |
| Other antiplatelet agent | 2 (4.3) | 2 (5.7) | 1 (4.0) | 1 (7.1) | 1 (6.2) | 1 (14.3) |
| Oral anticoagulant | 5 (10.9) | 5 (14.3) | 4 (16.0) | 3 (21.4) | 3 (18.8) | 0 (0.0) |
| Beta-blocker | 35 (76.1) | 18 (51.4) | 20 (80.0) | 11 (78.6) | 13 (81.2) | 5 (71.4) |
| Ivabradine | 11 (23.9) | 8 (22.9) | 2 (8.0) | 1 (7.1) | 0 (0.0) | 0 (0.0) |
| Calcium antagonists | 14 (30.4) | 11 (31.4) | 4 (16.0) | 4 (28.6) | 3 (18.8) | 2 (28.6) |
| Verapamil or dilitiazem | 4 (8.7) | 5 (14.3) | 2 (8.0) | 1 (7.1) | 1 (6.2) | 0 (0.0) |
| ACE inhibitors | 18 (39.1) | 14 (40.0) | 11 (44.0) | 6 (42.9) | 5 (31.2) | 3 (42.9) |
| AT II receptor-blocker | 15 (32.6) | 14 (40.0) | 7 (28.0) | 7 (50.0) | 7 (43.8) | 1 (14.3) |
| LLD | 42 (91.3) | 32 (91.4) | 23 (92.0) | 14 (100.0) | 15 (93.8) | 7 (100.0) |
| Statins (if LLD) | 36 (85.7) | 25 (78.1) | 17 (73.9) | 7 (50.0) | 10 (66.7) | 4 (57.1) |
| Other antianginal agent | 15 (32.6) | 12 (34.3) | 9 (36.0) | 8 (57.1) | 7 (43.8) | 3 (42.9) |
| Trimetazine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Ranolazine | 0 (0.0) | 1 (2.9) | 2 (8.0) | 3 (21.4) | 1 (6.2) | 1 (14.3) |
| Diuretics | 14 (30.4) | 16 (45.7) | 12 (48.0) | 9 (64.3) | 9 (56.2) | 3 (42.9) |
| Other hypertensive agent | 7 (15.2) | 8 (22.9) | 4 (16.0) | 4 (28.6) | 3 (18.8) | 1 (14.3) |
| Digoxin and derivates | 3 (6.5) | 2 (5.7) | 2 (8.0) | 1 (7.1) | 1 (6.2) | 0 (0.0) |
| Amiodarone/dronedarone | 2 (4.3) | 3 (8.6) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 1 (14.3) |
| Other antiarrhythmics | 0 (0.0) | 0 (0.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other medication | ||||||
| NSAIDs | 11 (23.9) | 6 (17.1) | 3 (12.0) | 2 (14.3) | 1 (6.2) | 1 (20.0) |
| Antidiabetic agents | 15 (32.6) | 5 (14.3) | 3 (12.0) | 1 (7.1) | 2 (12.5) | 0 (0.0) |
| PPI | 21 (45.7) | 15 (42.9) | 9 (36.0) | 6 (42.9) | 7 (43.8) | 3 (60.0) |
| THoR | 6 (13.0) | 5 (14.3) | 4 (16.0) | 2 (14.3) | 1 (6.2) | 0 (0.0) |
| HoR | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Drug for ED | 1 (2.2) | 1 (2.9) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
ACE angiotensin-converting enzyme, AT angiotensin, CAD coronary artery disease, ED erectile dysfunction, HoR hormone replacement therapy, LLD lipid-lowering drug, N number of patients, NSAIDs non-steroidal anti-inflammatory drugs, PPI proton pump inhibitor, THoR thyroid hormone replacement therapy
apercentages are of the data available